Welcome to our dedicated page for Argan SEC filings (Ticker: AGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Argan, Inc. (NYSE: AGX) is a Delaware corporation whose common stock is listed on the New York Stock Exchange, and it files periodic and current reports with the U.S. Securities and Exchange Commission. This SEC filings page brings together Argan’s Forms 10-K and 10-Q, as well as its frequent Form 8-K current reports, which disclose material events such as financial results, major project contracts and dividend declarations.
In its Form 8-K filings, Argan reports items like quarterly earnings releases under results of operations and financial condition, regular quarterly cash dividend announcements, and significant EPC contract awards received by subsidiaries such as Gemma Power Systems and Atlantic Projects Company. These filings also confirm key corporate details, including Argan’s state of incorporation, the AGX trading symbol and its New York Stock Exchange listing.
For investors and analysts, Argan’s annual reports on Form 10-K and quarterly reports on Form 10-Q provide more comprehensive information on segment performance, project backlog, risk factors and accounting policies, while current reports on Form 8-K highlight specific developments between reporting periods. Filings may also describe how new EPC contracts, full notices to proceed and backlog additions affect the company’s future activity.
On this page, AI-powered tools summarize lengthy SEC documents, highlight the main points from Argan’s 10-K and 10-Q filings, and explain the significance of individual 8-K items, such as dividend changes or large contract awards. Users can also review insider and executive-related filings like Form 4, along with proxy materials, to gain additional insight into Argan’s governance and equity activity.
Form 144 notice for Argan, Inc. (AGX) shows a proposed sale of 16,557 shares of common stock through Allen & Company on 09/19/2025, with an aggregate market value of $4,297,866.06. The filing lists 13,811,575 shares outstanding. The shares to be sold were acquired recently: 56,167 shares on 06/09/2025 via an equity grant (paid via option exercise) and 390 shares on 06/10/2025 as a time-based restricted stock issuance. The filer reports no securities sold in the past three months and includes the standard representation that no undisclosed material adverse information is known.
ARGAN, Inc. (AGX) submitted a Form 144 notifying the SEC of a proposed sale of 390 shares of common stock through Raymond James & Associates on 09/19/2025 with an aggregate market value of $103,014.60. The filing reports 13,811,575 shares outstanding for the issuer.
The 390 shares were acquired on 06/10/2025 as a time-based restricted stock issuance from the issuer and were paid on that same date. The filer reports no securities sold in the past three months and includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
ARGAN, Inc. (AGX) Rule 144 notice: The filer plans to sell 49,401 shares of common stock through Raymond James on the NYSE with an aggregate market value of $11,955,042, based on the filing. The shares reported for sale were acquired on 09/18/2025 as an equity grant from the issuer and the payment/transfer is listed as an option exercise on the same date. The filing also discloses two sales by the same person within the prior three months: 1,500 shares sold on 07/29/2025 for $362,250 and 5,000 shares sold on 07/31/2025 for $1,225,000. The filer represents no undisclosed material adverse information.
Peter W. Getsinger, a director of Argan Inc. (AGX), exercised stock options and sold a portion of the resulting shares in mid-September 2025. On 09/15/2025 he exercised the remaining 3,000 shares under an option granted 01/07/2016 at an exercise price of $30.44 per share using net settlement, resulting in a reported beneficial ownership of 15,505 shares. On 09/17/2025 he sold 2,609 shares on the open market at $239.68 per share, after which his reported beneficial ownership in common stock was 12,896 shares. The filing shows 3,000 option shares exercised and a remaining derivative position reported as 28,500 option-related shares.
Form 144 notice for ARGAN INC (AGX) reports a proposed sale of common shares by an insider through Morgan Stanley Smith Barney. The filer plans to sell 2,609 shares with an aggregate market value of $625,325.12 on the NYSE, and reports the acquisition of those shares on 09/17/2025 by exercising options under a registered plan and paying cash on the same date. The filing also discloses prior sales by the same person: 3,465 shares sold on 06/26/2025 for $734,630.59. The notice includes the seller's representation that no undisclosed material adverse information is known.
Rainer H. Bosselmann, identified as a former CEO & Director of Argan, Inc. (AGX), filed a Form 4 reporting a disposition of 196,723 shares on 09/15/2025. The filing states this is the reporting person's final filing because he has ended service as an officer/director and is no longer subject to Section 16 reporting. The Form 4 lists Bosselmann's mailing address as Arlington, VA, and shows the filing was signed by Beverley M. Bosselmann, Attorney-in-Fact.
Richard H. Deily, a former CFO and current officer of Argan, Inc. (AGX), reported transactions on 09/12/2025. The filing shows a sale of 7,802 shares of common stock. After the reported sale, the Form 4 lists the reporting persons remaining direct holdings in common stock attributable to outstanding equity awards: 10,000 shares underlying a 04/12/2020 option, 3,500 from a 04/16/2022 option, 2,500 from a 04/17/2024 option, 4,166 time-based RSUs scheduled to vest on 09/13/2025, and 7,500 of various performance-based RSUs/targets. The filing includes detailed vesting and payout conditions for the PRSUs and EPSRSUs with potential payouts from 0% to 200% depending on performance.
Argan, Inc. disclosed that its Board of Directors has approved a 33% increase in the regular quarterly cash dividend, raising it from $0.375 to $0.50 per common share. This higher dividend will be paid on October 31, 2025 to stockholders who are on record at the close of business on October 23, 2025. The change signals a larger ongoing cash return per share for investors through the company’s quarterly dividend program.
Argan, Inc. reports three reportable business segments and had 15,828,289 shares issued with 13,811,575 shares outstanding at July 31, 2025. The company is evaluating adoption of ASU 2023-09 on income tax disclosures. Approximately 26% of the remaining unrecognized performance obligations at July 31, 2025 are expected to be recognized in fiscal 2026, with the remainder in fiscal 2027–2029. The company has a revolving credit facility of $35.0 million priced at SOFR+1.85% with a $30.0 million accordion and a $25.0 million companion facility for letters of credit. Bonds covering warranty and retention obligations totaled $61.2 million. A $9.7 million letter of credit draw is disputed and included in accounts receivable. The IRS has disallowed R&D credits for fiscal 2021–2022; the company is contesting that finding and filed an insurance claim. Argan repurchased 56,117 shares for approximately $7.0 million during the six months ended July 31, 2025. Significant customer concentration remains in Power Industry Services, with top customers representing notable portions of revenue.
Argan, Inc. filed a current report to note that it has released financial results for the three months ended July 31, 2025. The company issued a press release on September 4, 2025 describing its results of operations and financial condition for this period.
The press release is included as Exhibit 99.1 and is incorporated by reference, while an inline XBRL cover page data file is included as Exhibit 104. The report is signed on behalf of Argan by Joshua S. Baugher, Senior Vice President, Chief Financial Officer and Treasurer.